|
|||||
|
|
Phase II study of cis-diamminedichloroplatinum in patients with non-small cell lung cancer |
|
| Authors: | J Fujita N Saijo K Eguchi E Shimizu T Shinkai K Tominaga Y Sasaki H Futami M Sakurai A Hoshi |
| Abstract: | A phase II study of cis-diamminedichloroplatinum (CDDP, 80 mg/m2, every 3 weeks) was performed in patients with non-small cell lung cancer (NSCLC). The overall response rate to CDDP was 14% (6/42). In patients without prior chemotherapy, the response rate was 20% (2/10), and in patients with prior chemotherapy, the response rate was 13% (4/31). The major side effect was gastrointestinal toxicity. It was concluded that CDDP at a dose of 80 mg/m2 every 3 weeks is effective against NSCLC. |
| Keywords: | |